.png)
We specialize in advancing late-stage preclinical CNS compounds through clinical development, turning promising preclinical discoveries into real-world therapies.
DCRM Sciences is a biopharmaceutical company focused on advancing late-stage preclinical therapeutics into the clinical stage.
DCRM was born to bridge the gap between preclinical promise and clinical success.
CNS illnesses are devastating and affect millions of families around the world. Our aim is to advance and invest in promising medicines for patients.
Driven by science, guided by precision, and committed to impact.
At DCRM Sciences, we’re focused on bringing new treatments for central nervous system disorders to patients as quickly and safely as possible.
We work exclusively with late-stage preclinical or IND-ready small molecule compounds.
Our streamlined approach to Phase 1 development is designed to move promising treatments forward without unnecessary delays.
DCRM Sciences pursues innovative MOAs and accelerates scientific breakthroughs.
Above all, safety is our top priority. We uphold the highest standards as we work to advance promising therapies that make a real difference in people's lives with these challenging conditions.